World Lung 2024 – ArriVent looks for lung cancer white space
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
Black Diamond picks its lung cancer battle
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
